Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.82 EUR | +0.52% | +10.23% | +3.09% |
May. 14 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.09% | 347M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.13% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix Raises EUR50.9 Million via Global Follow-on Offering